ICON (ICLR) and Advarra have entered a definitive partnership agreement to introduce a new ‘research-ready,’ connected site network model for clinical trials. The partnership will integrate ICON’s global clinical trial solutions and services with Advarra’s site CTMSs, eISF, and eSource systems, which are already used by more than 50,000 investigators worldwide, including researchers at 90 of the top 125 academic medical centers, 90 percent of NCI-Designated Cancer Centers, and the top site networks. This approach leverages Advarra’s Study Collaboration as the connector to ICON’s proprietary technology to create a shared operating environment for ICON studies that reduces administrative friction, accelerates study startup, and increases clinical trial participation.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ICLR:
- ICON plc options imply 2.8% move in share price post-earnings
- Icon price target lowered to $120 from $200 at Citi
- ICON plc options imply 4.1% move in share price post-earnings
- Icon price target lowered to $120 from $200 at Barclays
- Icon plc: Valuation Overhang and Revenue Timing Issues Create Compelling Buy‑Rated Risk‑Reward Opportunity
